Memphasys Ltd
Memphasys Limited is an Australia-based reproductive biotechnology company.
The business
Memphasys Limited is an Australia-based reproductive biotechnology company. The Company is engaged in developing medical devices, diagnostics, and media with application to assisted reproductive technology (ART) in humans and animals. The Company's product pipeline includes Felix, RoXsta, and AI-Port. Its advanced product, the Felix System, is a patented automated device for quickly and gently separating sperm from a semen sample for use in ART procedures. The Felix device consists of two main components: a console, which supplies electrical power, and a sterile disposable cartridge for sperm isolation and selection. RoXsta is an in-vitro diagnostic device that assesses semen and other bodily fluids for oxidative stress load. RoXsta also has an application as part of a suite of products that can support the animal industry. AI-Port has been developed for the purpose of maintaining the viability of livestock semen for up to seven days at a temperature range of 22 - 25 degrees Celsius.
Small Caps Research
No research on Memphasys Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise MEM based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news

Memphasys Signs Distribution Deal for Felix Fertility Device into IVF Clinics throughout Vietnam
Memphasys inks $530,000 Vietnam deal to distribute Felix fertility device through TMSC Vietnam, marking first SE Asia partnership and rapid IVF market expansion.

Memphasys Prepares for First Australian Sales after Felix Sperm Separation Device Gains TGA Approval
Memphasys (ASX: MEM) gains TGA approval for Felix device, enabling immediate Australian sales and clinic deployments two months ahead of schedule.

Memphasys Secures CE Mark for Felix System, Unlocking European Market
Memphasys (ASX: MEM) has secured CE Mark approval for its Felix System, unlocking immediate commercial opportunities in Europe and activating binding multi-year contracts in Europe and MENA.

Memphasys Signs Agreement to Distribute Felix Fertility Device Across Middle East and North Africa
Memphasys (ASX: MEM) has granted Qatar-based company International Technical Legacy (ITL) exclusive commercial and distribution rights to its innovative Felix male fertility sperm preparation system. The five-year deal applies to approximately 353 clinics across 15 countries across the Middle East and North Africa, which perform a cumulative 140,000 in vitro fertilisation (IVF) cycles per year. […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.